Stock PCVX VAXCYTE, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Vaxcyte, Inc.

Equities

PCVX

US92243G1085

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 01:30:00 02/05/2024 am IST 		5-day change 1st Jan Change
63.71 USD +5.22% Intraday chart for Vaxcyte, Inc. +5.66% +1.45%
25/04 Vaxcyte Insider Sold Shares Worth $928,845, According to a Recent SEC Filing MT
22/04 Vaxcyte Insider Sold Shares Worth $490,199, According to a Recent SEC Filing MT

Business Summary

Vaxcyte Inc. is a clinical-stage vaccine company. It is engaged in developing a spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its lead candidate, VAX-24, is a Phase III-ready 24-valent, carrier-sparing pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD). VAX-31, the Company’s next generation 31-valent PCV is developed for the prevention of IPD in adults. Its pipeline also includes VAX-A1, VAX-PG, and VAX-GI. VAX-A1, a novel conjugate vaccine candidate designed to prevent disease caused by Group A Streptococcus (Group A Strep). VAX-PG, a novel protein vaccine candidate targeting pathogen responsible for periodontitis, a chronic oral inflammatory disease. VAX-GI, a novel preclinical vaccine candidate being developed as a preventative treatment for dysentery and shigellosis. Its technology platform includes advanced chemistry and the XpressCF cell-free protein synthesis platform.

Number of employees: 254

Managers

Managers TitleAgeSince
Jeff Fairman FOU
 Founder 60 27/13/27
Grant Pickering FOU
 Founder 56 27/13/27
Andrew Guggenhime DFI
 Director of Finance/CFO 55 01/20/01
Jakub Simon CTO
 Chief Tech/Sci/R&D Officer - 11/22/11
Mikhail Eydelman CMP
 Compliance Officer 43 01/22/01
James Wassil COO
 Chief Operating Officer 54 01/19/01
Janet Graesser IRC
 Investor Relations Contact - 01/21/01
Elvia Cowan PRN
 Corporate Officer/Principal 51 01/22/01
Whitney Jones HRO
 Human Resources Officer - 16/01
Harpreet Dhaliwal PRN
 Corporate Officer/Principal - 29/21/29

Members of the board

Members of the board TitleAgeSince
Grant Pickering FOU
 Founder 56 27/13/27
Anne Seibold Drapeau BRD
 Director/Board Member 58 16/21/16
Michael Kamarck BRD
 Director/Board Member 73 27/21/27
Heath Lukatch BRD
 Director/Board Member 57 01/18/01
K. Hirth BRD
 Director/Board Member 72 01/16/01
Halley Gilbert BRD
 Director/Board Member 54 01/20/01
Carlos Paya CHM
 Chairman 65 27/21/27
Teri Loxam BRD
 Director/Board Member 51 16/21/16
Jacks Lee BRD
 Director/Board Member - 27/11

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 108,759,448 107,016,315 ( 98.40 %) 0 98.40 %

Shareholders

NameEquities%Valuation
Fidelity Management & Research Co. LLC
13.11 %
14,213,365 13.11 % 971 M $
Vanguard Fiduciary Trust Co.
7.797 %
8,452,371 7.797 % 577 M $
BlackRock Advisors LLC
7.361 %
7,980,394 7.361 % 545 M $
RA Capital Management LP
7.279 %
7,891,254 7.279 % 539 M $
Janus Henderson Investors US LLC
6.440 %
6,981,376 6.440 % 477 M $
Wellington Management Co. LLP
4.088 %
4,431,920 4.088 % 303 M $
Capital Research & Management Co. (Global Investors)
3.173 %
3,440,107 3.173 % 235 M $
STATE STREET CORPORATION
3.127 %
3,389,528 3.127 % 232 M $
T. Rowe Price International Ltd.
2.470 %
2,677,822 2.470 % 183 M $
Geode Capital Management LLC
1.820 %
1,973,506 1.820 % 135 M $

Company contact information

Vaxcyte, Inc.

825 Industrial Road Suite 300

94070, San Carlos

+650 837 0111

http://www.vaxcyte.com
address Vaxcyte, Inc.(PCVX)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
63.71 USD
Average target price
103.3 USD
Spread / Average Target
+62.12%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VAXCYTE, INC. Stock Vaxcyte, Inc.
+1.45% 6.93B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-1.17% 104B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+2.87% 97.47B
ARGENX SE Stock argenx SE
+4.13% 22.25B
BIONTECH SE Stock BioNTech SE
-14.77% 21.68B
GENMAB A/S Stock Genmab A/S
-8.56% 18.2B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-39.98% 17.02B
BEIGENE, LTD. Stock BeiGene, Ltd.
-13.21% 16.36B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+8.55% 14.39B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+35.75% 12.37B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. PCVX Stock
  4. Company Vaxcyte, Inc.